The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin’s lymphoma

Published:2008-11-12 Issue:5 Volume:88 Page:425-432
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Yang Deok-Hwan,Min Jung-Joon,Jeong Yong Yeon,Ahn Jae-Sook,Kim Yeo-Kyeoung,Cho Sang-Hee,Chung Ik-Joo,Bom Hee-Seung,Kim Hyeoung-Joon,Lee Je-Jung

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-008-0616-3.pdf

Reference27 articles.

1. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419

2. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433

3. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma—comparison with CT. Leuk Lymphoma 39:543–553

4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244

5. Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL, Jaffe ES et al (1988) Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6:1832–1837

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. El papel de los parámetros metabólicos de la 18F-FDG PET/TC en el linfoma linfoblástico pediátrico;Revista Española de Medicina Nuclear e Imagen Molecular;2022-03

2. Fundamentals of Radiomics in Nuclear Medicine and Hybrid Imaging;Basic Sciences of Nuclear Medicine;2021

3. The role of 18F-FDG PET/CT metabolic parameters in pediatric lymphoblastic lymphoma;Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2021-01

4. Tonsil non-Hodgkin lenfomalı hastaların değerlendirilmesinde FDG-PET/BT'nin değeri;Cukurova Medical Journal;2018-06-30

5. Contrast‑enhanced computed tomography combined with Chitosan‑Fe3O4 nanoparticles targeting fibroblast growth factor receptor and vascular endothelial growth factor receptor in the screening of early esophageal cancer;Experimental and Therapeutic Medicine;2018-04-23